Belharra Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
A chemoproteomics company discovering small-molecule drugs for elusive targets in oncology and immunology.
OncologyImmunology
Technology Platform
A photoaffinity-based chemoproteomics platform that globally profiles small-molecule interactions with the native proteome to identify novel druggable sites.
Funding History
1Total raised:$50M
Series A$50M
Opportunities
The platform has the potential to systematically generate new, patentable chemical starting points for high-value targets across multiple disease areas.
Risk Factors
The novel chemistry and biology identified require extensive validation, and the path from a discovered interaction to a clinical drug is long and risky.
Competitive Landscape
Part of a vanguard of chemoproteomics companies racing to translate novel binding site discoveries into viable clinical candidates.